论文部分内容阅读
将90名初发T2DM患者随机分配到不同胰岛素使用组(诺和灵30R、诺和锐30、甘精胰岛素),每组30名患者。治疗12周,结果 3组血糖、Hb A1c、HOMA-IR均较治疗前降低,HOMA-β升高,BMI及空腹血糖甘精胰岛素组低于其他两组(P<0.05),诺和锐30组和甘精胰岛素组HOMA-β高于诺和灵30R(P<0.05),甘精胰岛素低血糖发生率低。结论胰岛素均能有效控制初发T2DM甘精胰岛素联合口服降糖药效果不劣于预混胰岛素,且低血糖发生率低、患者治疗依从性好。
Ninety patients with newly diagnosed T2DM were randomly assigned to 30 insulin treatment groups (noradren 30R, NovoRay 30, insulin glargine). After 12 weeks of treatment, blood glucose, HbA1c and HOMA-IR of the three groups were lower than those before treatment, HOMA-β was increased, BMI and fasting plasma glucose level were lower than the other two groups (P <0.05) HOMA-β in group and insulin glargine group were higher than those in norepinephrine 30R group (P <0.05), insulin glargine hypoglycemia was low. Conclusion Insulin can effectively control the initial onset of insulin combined with oral hypoglycemic insulin ganoderma better than premixed insulin, and low incidence of hypoglycemia, patients with good compliance treatment.